Over 60% of pharma MSMEs yet to comply with updated manufacturing norms

Pharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shortages, funding constraints, and rising compliance costs pose challenges for smaller drug makers within the SME ecosystem..

Raccontata daeconomictimes.indiatimes.com